Is Orthofix Medical, Inc. overvalued or undervalued?

As of 30 April 2021, the valuation grade for Orthofix Medical, Inc. moved from expensive to risky. The company is currently assessed as overvalued. Key ratios indicate significant financial distress, with a Price to Book Value of 0.94, an EV to EBIT of -5.37, and an EV to EBITDA of -27.66. The company's return on capital employed (ROCE) stands at -17.66%, and return on equity (ROE) is at -29.97%, highlighting severe operational challenges.
In comparison to its peers, Orthofix Medical, Inc. has a P/E ratio of -3.0011, while Artivion, Inc. shows a much higher P/E of -111.7792, and IRadimed Corp. is at a fair valuation with a P/E of 37.2618. The company has underperformed significantly against the S&P 500, with a year-to-date return of -38.14% compared to the index's 2.44%. Overall, these indicators suggest that Orthofix Medical, Inc. is not only overvalued but also facing substantial risks in its current financial situation.